Aortic Valve (TAVR/TAVI)Friday, September 25, 2026
Semaglutide is improving the heart health of millions—but how? Experts are stumped - Cardiovascular Business
1 min read·By E. Nolan Beckett, MD·Source: Cardiovascular Business
From The Valve Wire
The single-center two-era analysis published in Medical Sciences is the day's most instructive TAVR data — and its most misread.
Comparing 100 consecutive isolated TAVRs from 2012 with 100 from 2024, the 30-day composite of death or stroke fell from 10% to 1%, PVL ≥mild dropped from 27% to 3%, and hospital stay collapsed from 6 to 1 day (unadjusted, single-center, N=100 per era).
Editor’s take pending for this article; this is the section commentary excerpt.
Source Abstract
Semaglutide is improving the heart health of millions—but how? Experts are stumped Cardiovascular Business
Read the Original
Full article at Cardiovascular Business
Open at Cardiovascular Business →The Valve Wire summarizes; we link out to primary sources for verification.
More in Aortic Valve (TAVR/TAVI)
- Aortic Valve (TAVR/TAVI)· Cardiovascular intervention and therapeuticsTAVI-TEC: an AI-based tool for procedural planning of transcatheter aortic valve implantation.
- Aortic Valve (TAVR/TAVI)· JACC. AdvancesMitral Regurgitation after TAVR: Sex Differences and Low-Flow Low-Gradient Aortic Stenosis.
- Aortic Valve (TAVR/TAVI)· Frontiers in cardiovascular medicineCase Report: Brugada syndrome uncovered by delivery in a 32-year-old patient.
Elsewhere in Today’s Issue
- Mitral Valve (Repair & Replacement)· JACC. Case reportsParallel Septal Balloon Occlusion for Acute Right-to-Left Shunt During Mitral Transcatheter Edge-to-Edge Repair.
- Mitral Valve (Repair & Replacement)· JACC. AdvancesVery Severe, Not Too Severe: Reconsidering LV Dysfunction as a Barrier to Mitral TEER.
- Mitral Valve (Repair & Replacement)· Journal of cardiovascular echographyHigh Incidence of Short-term Subsequent Atrial Fibrillation Following Restrictive Filling Mitral Flow Profile in Patients without Structural Heart Disease.